Sirolimus for the treatment of children with various complicated vascular anomalies. - Wikidata - awgldk - TriplyDB

Sirolimus for the treatment of children with various complicated vascular anomalies.

Sirolimus for the treatment of children with various complicated vascular anomalies.

http://www.wikidata.org/entity/Q35651949

about

Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects [Lymphatic malformations in the head and neck area].Defective autophagy is a key feature of cerebral cavernous malformations.Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling Somatic PIK3CA mutations as a driver of sporadic venous malformations.Modeling lymphangiosarcoma in mice.Treatment of cystic hygroma in a young infant through multidisciplinary approach involving sirolimus, sclerotherapy, and debulking surgery Clinical Efficacy of Herbal Medicine for Pediatric Lymphatic Malformations: A Pilot Study.Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.Sleep-disordered breathing in pediatric head and neck vascular malformations.Angiopoietins as serum biomarkers for lymphatic anomalies.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Long-Term Follow-Up of Lymphatic Malformations in Children Treated with Sildenafil.Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients.Fibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients.Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement.Advances in the Medical Management of Vascular Anomalies.Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.Gorham-Stout Disease of the Skull Base With Hearing Loss: Dramatic Recovery and Antiangiogenic Therapy.Nursing Implications for the Management of Lymphatic Malformation in Children [Formula: see text].Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study

P2860

Q27333126-5753AA66-D026-460E-A212-7E5630BBB610 Q35906928-8D020FDC-01D5-4330-BFC0-E1A1E20FF80A Q36278717-3D19923F-9A84-4B0A-A1BB-2F04679303BE Q36518788-075502C3-84B4-4689-86ED-F43CE76C2DDF Q36788733-6C7D8620-3E2A-454F-ADCC-5892494AC2C9 Q37130685-9C63C747-AE7E-4507-A236-81335CDEC2BC Q37143063-FFBCA86D-5A60-483F-8640-BCDF67078FFF Q37223197-1F423145-DED1-4F55-87BE-6A6841CB0F67 Q37343920-E9BCAC22-5FB1-4E3C-A002-2C10DE6B7671 Q37490783-96127CB5-7065-479B-83F2-D7540F92D08D Q38958282-C7157705-16CD-49D0-914E-9DA572FAE56E Q39155894-CDB89890-89BA-4EE9-A09A-A6DAB365199F Q39206695-773D15EF-8D83-4650-A4B0-FA924C7266BE Q40379265-27134C63-66B5-4502-A642-48E4AFEAE02E Q40418897-7EAC298C-5FF9-4094-9385-B5F07D09BB98 Q41970819-CAB47695-74BB-44B1-958D-ABB2A0C2254B Q46135289-70B63835-F3DF-4224-807C-CB6132E18117 Q47438107-3C84A96C-BD85-40B6-A086-A6607ACF3233 Q48292344-E58E9B7A-A1BC-4E6B-94FC-BEC6BB10348B Q48319339-E946D432-6E92-4A9F-9225-4617685BB7FC Q49711115-FA5C3971-D28D-405C-8441-FA0F9987E571 Q49711122-B9B0054D-0113-49E3-B559-294EF14557AF Q50317318-33D04709-20DC-439E-9467-BFDCF845347B Q51511937-F442B976-6F97-48B6-868E-4954B30A050D Q51584251-CB2D4440-35A9-4EDA-BC58-959A8547EBBD Q55539095-EC0E05B7-88B8-42E0-A152-67A831897BDA Q58106291-5969CC8A-4DCA-451A-9446-AA823E2E2C54

P2860

Sirolimus for the treatment of children with various complicated vascular anomalies.

http://www.wikidata.org/entity/Q35651949

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sirolimus for the treatment of children with various complicated vascular anomalies.

@ast

Sirolimus for the treatment of children with various complicated vascular anomalies.

@en

type

label

Sirolimus for the treatment of children with various complicated vascular anomalies.

@ast

Sirolimus for the treatment of children with various complicated vascular anomalies.

@en

prefLabel

Sirolimus for the treatment of children with various complicated vascular anomalies.

@ast

Sirolimus for the treatment of children with various complicated vascular anomalies.

@en

P1433

Q35651949-9F2BECB9-9501-42BA-B0ED-C736ECEB7530

P1476

Q35651949-48D23DFA-A014-4B6F-9A66-4CDC2F6EE7D5

P2093

Q35651949-03572C8C-6FAE-4A07-8770-E91B02FC670B

Q35651949-041CCF6A-B42D-4735-B58D-1E77A692725C

Q35651949-13898749-5AB7-4B37-9234-C8F3F858576E

Q35651949-173DFFBA-E7D3-47C8-97F8-D13D177C6AED

Q35651949-A12E06C1-7CE2-43D4-A9F9-7462F421E9F0

Q35651949-A4490238-C1E7-4871-96C7-395B8DA49C07

Q35651949-AE51716C-E584-4E3A-A176-6DFF2B1D2B62

Q35651949-D7A0C419-8A86-4308-80F7-E19FC02276E6

Q35651949-E0633244-EC09-4FCF-A155-BB90405118D3

Q35651949-F36A6A25-C51A-4852-BB67-772AFB88C7F2

P2888

Q35651949-07478E92-F60C-4F8D-A6E1-71404A7781EF

P304

Q35651949-6761277E-AB2B-42EA-8F77-1205F554C133

P31

Q35651949-208B55E7-A928-453C-94C2-5985C2BE228E

P356

Q35651949-3E839F52-63A8-4802-AAB9-BB76495E66FF

P433

Q35651949-9BD19A84-C9C8-4998-A3F5-CE0C17D30A09

P478

Q35651949-3DFB83DB-2C5D-44FF-A4BD-504A0F4F500D

P50

Q35651949-069F3A40-BD42-4705-9345-D3E5FB0C482E

P577

Q35651949-8E264D72-1BB9-4575-B68D-68B1385EAA27

P5875

Q35651949-68A0AFE8-0914-429E-A921-E7B91F1C5111

P698

Q35651949-86DCE226-2D53-4548-BA90-1A2ADE253C73

P356

S00431-015-2572-Y

P1433

European Journal of Pediatrics

P1476

Sirolimus for the treatment of children with various complicated vascular anomalies

@en

P2093

Anna Karastaneva

http://www.w3.org/2001/XMLSchema#string

Christian E Urban

http://www.w3.org/2001/XMLSchema#string

Daniela Sperl

http://www.w3.org/2001/XMLSchema#string

Emir Haxhija

http://www.w3.org/2001/XMLSchema#string

Erich Sorantin

http://www.w3.org/2001/XMLSchema#string

Friedrich Reiterer

http://www.w3.org/2001/XMLSchema#string

Herwig Lackner

http://www.w3.org/2001/XMLSchema#string

Martin Benesch

http://www.w3.org/2001/XMLSchema#string

Petra Sovinz

http://www.w3.org/2001/XMLSchema#string

Sofia Lanz

http://www.w3.org/2001/XMLSchema#string

P2888

s00431-015-2572-y

P304

1579-1584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00431-015-2572-Y

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P50

Markus G. Seidel

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277781176

http://www.w3.org/2001/XMLSchema#string

P698

26040705

http://www.w3.org/2001/XMLSchema#string